SCHEMBL2296073

SCHEMBL2296073

CC(C)C(NC(=O)c1cc(-c2ccc(NC(=O)Nc3ccc(-c4cc(C(=O)NC(C(=O)O)C(C)C)on4)cc3)cc2)no1)C(=O)O

nearest known ligand 0.92

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CSGALNACT1 Q8TDX6 20/20 0.92

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2294362 0.97 CSGALNACT1 (0.86) CSGALNACT1
SCHEMBL2294376 0.97 CSGALNACT1 (0.86) CSGALNACT1
SCHEMBL2300772 0.96 CSGALNACT1 (1.00) CSGALNACT1
SCHEMBL2294481 0.95 CSGALNACT1 (0.83) CSGALNACT1
SCHEMBL2293666 0.95 CSGALNACT1 (0.84) CSGALNACT1
SCHEMBL2294065 0.95 CSGALNACT1 (0.83) CSGALNACT1
SCHEMBL2298598 0.95 CSGALNACT1 (1.00) CSGALNACT1
SCHEMBL2298584 0.95 CSGALNACT1 (1.00) CSGALNACT1
SCHEMBL2300240 0.95 CSGALNACT1 (0.84) CSGALNACT1
SCHEMBL2299627 0.94 CSGALNACT1 (0.88) CSGALNACT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US claimed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US claimed
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US disclosed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT CSGALNACT1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.